RNA binding motif protein 17 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored RBM17P4 profile across patient tissues and cancer cell-line models. RBM17P4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM17P4 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RBM17P4 RNA expression shows 12,289 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where RBM17P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM17P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM17P4 survival associations across molecular data types. RBM17P4 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM17P4 RNA expression–survival associations across cancer types. High RBM17P4 expression shows unfavorable associations in KIRC, HNSC, STAD, LAML and KIRP, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM17P4 RNA expression.
This table summarizes RBM17P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RBM17P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM17P4 shows lower tumor expression in ESCA and higher tumor expression in COAD, HNSC and STAD. The COAD box plot shows higher RBM17P4 RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p < 0.001).
This table shows molecular features associated with RBM17P4 in patient tissues and cancer cell lines. In patient samples, RBM17P4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
